الصفحة الرئيسية

كلية الصيدلة \ الكيمياء الصيدلة

كامل عبدالرحيم متولي بيومي

السيرة الذاتية
نسبة اكتمال الملف الشخصي
الجنسية المصرية
التخصص العام الكيمياء الصيدلية
التخصص الدقيق الكيمياء الدوائية
المسمى الوظيفي استاذ
الدرجة العلمية (المرتبة) دكتوراه

نبذه مختصرة

Dr Kamel A Metwally, Professor of Medicinal Chemistry, Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Tabuk I had PhD in Medicinal Chemistry from Zagazig University (Egypt), according to a channel program with Virginia Commonwealth University (Virginia, USA), under the title "design and synthesis of novel 5-HT2 ligands" Master degree in Medicinal Chemistry, was awarded from Zagazig University under the title "synthesis and pharmacological study of some new arylpropionic acid derivatives My research interests include the design and synthesis of novel tyrosine kinase inhibitors as anticancer agents design and synthesis of aldose reductase inhibitors as potential therapeutic agents for the prevention of diabetic complications and design and synthesis of novel anticancer agents targeting tubulin

المؤهلات العلمية

PhD 1998: Medicinal Chemistry, Virginia Commonwealth University (USA) according to a channel program with Zagazig University (Egypt) Title of dissertation: “Design and synthesis of novel 5-HT2 ligands MSc 1995: Medicinal Chemistry, Faculty of Pharmacy, Zagazig University Title of thesis: “Synthesis and pharmacological study of some new arylpropionic acid derivatives BSc 1990:Phar maceutical Sciences, Faculty of Pharmacy, Zagazig University “Excellent with honor degree the first out of ~ 150 students

الاهتمامات البحثية

Design and synthesis of novel tyrosine kinase inhibitors as anticancer agents Design and synthesis of aldose reductase inhibitors as potential therapeutic agents for the prevention of diabetic complications Design and synthesis of novel anticancer agents targeting tubulin

الخبرات والمناصب الإدارية

• Supervisor of measurement, assessment, and evaluation unit, Faculty of Pharmacy, University of Tabuk, Tabuk, Kingdom of Saudi Arabia (May 2021 to date) • Supervisor of FPUT strategic plan implementation, Faculty of Pharmacy, University of Tabuk, Tabuk, Kingdom of Saudi Arabia (May 2021 to date) • Professor of Medicinal Chemistry, Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Tabuk, Tabuk, Kingdom of Saudi Arabia (March 2021 to date) • Head of Medicinal Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt (August 2018 – March 2021) • Professor, Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt (March 2018 - to date) • Assistant Professor, Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt (July 2012- March 2018) • Member, “Scientific Council of King Faisal University, (Two terms, starting April 2010) Selected unanimously by King Faisal University Council and approved by Saudi Minister of Higher Education in both terms • Member, “Translation, Authorship and Publication Center of King Faisal University (Two terms, starting January 2010) Selected unanimously by King Faisal University Council • Associate Professor, Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, KSA (September 2006- July 2012) • Lecturer, Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University (October 2001- September 2006) • Part-time Lecturer, Department of Pharmaceutical Chemistry, School of Pharmacy, Misr International University (MIU), Obour City, Egypt (September 2003 to September 2005) • Postdoctoral Fellow, Department of Medicinal Chemistry, School of Pharmacy, Medical College of Virginia, Virginia Commonwealth University, Virginia, USA funded by the American university (October 2000- October 2001) • Lecturer, Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University (October 1998- October 2000) • Teaching Assistant Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University (April 1998 - October 1998) • PhD research scholar, School of Pharmacy, Medical College of Virginia, Virginia Commonwealth University, Virginia, USA (April 1996 to April 1998) • Teaching Assistant Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University (March 1995- April 1996) • Demonstrator Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University (September 1990- March 1995)

الجدول الدراسي
اليوم المادة الوقت
من إلى
الأحد Introductory Medicinal Chemistry 09:00 12:00
الأحد Office hours (3rd year - Male - 148) 12:00 14:00
الإثنين Academic advising 09:00 11:00
الإثنين Clinical Biochemistry (Field training) 13:00 15:00
الثلاثاء Office hours (4th year - Male - 1536) 12:00 14:00
الأربعاء Medicinal Chemistry-2 (Female section) 08:00 11:00
الأربعاء Office hours (4th year - Female - 104) 11:00 13:00
الخميس Medicinal Chemistry-2 (Male section) 10:00 13:00
الخميس Field Pharmaceutical training-3 13:00 17:00
الأبحاث والمؤلفات
  • 1) El-Sadek, M, Abdel Aziz, L, and Metwally, K Synthesis and biological activity of certain flurbiprofen derivatives Zagazig J Pharm Sci, 5, 29-35 (1996) 2) El-Sadek, M, Abdel-Aziz, L, Abou-Kull, M, and Metwally, K Synthesis and biological evaluation of novel heterocyclic derivatives of flurbiprofen Zagazig J Pharm Sci, 7, 94-100 (1996) 3) Metwally, K, Dukat, M, and Glennon, R Azaspirodecanones: structure-affinity relationships for 5-HT2A serotonin receptor binding Virginia J Sci, 48, 141 (1997) 4) Metwally, K, Dukat, M, Egan, C, Smith, C, DuPre, A, Gauthier, C, Herrick-Davis, K, Teitler, M, and Glennon, R Spiperone: influence of spiro ring substituents on 5-HT2A serotonin receptor binding J Med Chem, 41, 5084-5093 (1998) 5) Lashine, E, El-Adl, S, Metwally, K, and Abou-Kull, M Synthesis of some new quinoline derivatives of potential antimicrobial activity Zagazig J Pharm Sci, 8, 23-27 (1999) 6) El-Adl, S, Metwally, K, and Abou-Kull, M Utility of dichloromaleimide derivative as a chromogenic reagent for the spectrophotometric determination of certain fluoroquinolones and related compounds Zagazig J Pharm Sci, 8, 13-17 (1999) 7) Glennon, R, Metwally, K, Dukat, M, Ismaiel, A, De Los Angeles, J, Herndon, J, Teitler, M, and Khorana, M Ketanserin and spiperone as templates for novel serotonin 5-HT2A antagonists Curr Top Med Chem, 539-558, 2, (2002) 8) Sukkar, O, Metwally, K, Abu Koll, M and El-Adl, S Increasing sensitivity of colorimetric determination of basic drugs through ion pair complex formation Zagazig J Pharm Sci, 14, 32-39 (2005) 9) Metwally, K, Abdel-Aziz, L, Lashine, E, Husseiny, M and Badawy, R Hydrazones of 2-arylquinoline-4-carboxylic acid hydrazides: synthesis and preliminary evaluation as antimicrobial agents Bioorg Med Chem, 14, 8675-8682 (2006) 10) Metwally, K, Yaseen, S, Lashine, E, El-Fayomi, H and El-Sadek, M Non-carboxylic analogues of aryl-propionic acids: synthesis, anti-inflammatory activity and ulcerogenic potential Eur J Med Chem, 42, 152-160 (2007) 11) Metwally, K, Pratsinis, H, and Kletsas, D Pyrimido[4,5-c]quinolin-1(2H)-ones as a novel class of antimitotic agents: synthesis and in vitro cytotoxic activity Eur J Med Chem, 42, 344-350 (2007) 12) Metwally, K, Aly, O, Aly, E, Banerjee, A, Ravindra, R and Bane, S Synthesis and biological activity of 2,5-diaryl-3-methyl-pyrimidino[4,5-c]quinolin-1(2H)-one derivatives Bioorg Med Chem, 15, 2434-2440 (2007) 13) Metwally K, Aly, E, Aly, O and El-Nabtity S Spirohydantoins derived from 1-tetralone: design, synthesis and exploration of their anticonvulsant activity and neurotoxicity Bull Fac Pharm Cairo Univ, 45, 149-154 (2007) 14) Metwally K, Khalil A, Pratsinis, H, Kletsas, D Synthesis, in-vitro Cytotoxicity, and a Preliminary Structure-Activity Relationship Investigation of Pyrimido[4,5-c]quinolin-1(2H)-ones Arch Pharm Life Sci, 43, 465-72 (2010) 15) Attia G, Metwally K, El-Bayoumy S, Lashine S Optimization of labelling conditions and biodistribution of 99mTc-celecoxib for inflammation imaging Arab J Nucl Sci App, 43(4), 33-41 (2010) 16) Metwally K, Khalil A, Pratsinis, H, Kletsas, D, Asmaa Sallam, Khalid El-Sayed Structure-activity relationship investigation of methoxy substitution on anticancer pyrimido[4,5-c]quinolin-1(2H)-ones Med Chem Res, 22, 4481-4491 (2013) 17) Metwally, K, Pratsinis, H, and Kletsas, D The antimitotic pyrimido[4,5-c]quinolin-1(2H)-one scaffold: probing substituents at position 3 Med Chem Res, 24, 2604-2611 (2015) 18) Abdel-Aziz M, Metwally K, Gamal-Eldeen A, Aly O 1,3,4-Oxadiazole-2-thione derivatives novel approach for anticancer and tubulin polymerization inhibitory activities Anticancer Agents Med Chem, 16(2), 269-77 (2015) 19) Eissa A, Blaxland J, Williams R, Metwally K, El-Adl S, Lashine E, Baillie L, Simons C Targeting methionyl tRNA synthetase: design, synthesis and antibacterial activity against Clostridium difficile of novel 3-biaryl-N-benzylpropan-1-amine derivatives J Enzyme Inhib Med Chem, 31(6), 1694-1697 (2016) 20) Eissa A, Blaxland J, Williams R, Metwally K, El-Adl S, Lashine E, Baillie L, Simons C Adenine and benzimidazole-based mimics of REP-3123 as antibacterial agents against Clostridium difficile and Bacillus anthracis: Design, synthesis and biological evaluation Bull Fac Pharm Cairo Univ, 54, 197-207 (2016) 21) Metwally, K Pratsinis, H Kletsas, D Novel 2,4- thiazolidinediones: Synthesis, in vitro cytotoxic activity, and mechanistic investigation Eur J Med Chem 133, 340-350 (2017) 22) El-Sayed S Metwally, K Abdel-Aziz, L El-Shanawani, A El-Rashidy, A Soliman, M Quattrini, L Coviello, V La Motta, C Quinazolinone-based rhodanine-3-acetic acids as potent aldose reductase inhibitors: synthesis, functional evaluation and molecular modeling study Bioorg Med Chem Lett, 27, 4760-4764 (2017) 23) Metwally, K Pratsinis, H Dimitris, D Quattrini, L Coviello, V La Motta, C El-Rashidy, A Soliman, M Novel quinazolinone-based 2,4-thiazolidinedione-3-acetic acid derivatives as potent aldose reductase inhibitors Future Med Chem, 9(18), 2147-2166 (2017) 24) El-Sayed, Sh Metwally, K El-Shanawani, A Abdel-Aziz, L Pratsinis, H Kletsas, D Synthesis and anticancer activity of novel quinazolinone-based rhodanines Chemistry Central Journal, 11:102, 1-10 (2017) 25) Crespo, I Giménez-Dejoz, J Porté, S Cousido-Siah, A Mitschler, A Podjarny, A Pratsinis, H Kletsas, D Parés, X Ruiz, F, Metwally, K Farrés, J Design, synthesis, structure-activity relationships and X-ray structural studies of novel 1-oxopyrimido[4,5-c]quinoline-2-acetic acid derivatives as selective and potent inhibitors of human aldose reductase Eur J Med Chem, 152, 160-174 (2018) 26) Jiménez R, Pequerul R, Amor A, Lorenzo J, Metwally K, Avilés F, Parés X, Farrés J Inhibitors of aldehyde dehydrogenases of the 1A subfamily as putative anticancer agents: Kinetic characterization and effect on human cancer cells Chem Biol Interact, 306, 123-130 (2019) 27) Froes T, Guido R, Metwally K, Castilho M A novel scaffold to fight P aeruginosa pyocyanin production: Early-steps to novel anti-virulence drugs Future Med Chem, 12(16), 1489-1503 (2020) 28) Abou-Elkhair R, Wasfy A, Mao S, Du, J, Eladl S, Metwally, K, Hassan A and Sheng J 2-Hydroxyimino-6-aza-pyrimidine nucleosides: synthesis, DFT calculations, and antiviral evaluations New Journal of Chemistry, 44, 19650-19662 (2020) 29) Yahya, G, Mohamed, N, Pijuan, J, Seleem, N, Mosbah, R, Hess, S, Abdelmoaty, A, Almeer, R, Abdel-Daim, M, Alshaman, H, Juraiby, I, Metwally, K, Storchova, Z Profiling the physiological pitfalls of anti-hepatitis C direct-acting agents in budding yeast Microb Biotechnol, 14(5), 2199-2213 (2021)
جوائز التميز
  • 1- The First of Class Honor (1990): Faculty of Pharmacy, Zagazig University 2- Egyptian Syndicate of Pharmacists Award for distinguished academic pharmacists (1995) 3- Egyptian Syndicate of Pharmacists Award for distinguished academic pharmacists (1999) 4- Zagazig University Research Award for distinguished researchers (2007) 5- Outstanding reviewer 2015, European Journal of Medicinal Chemistry (2015) 6- Zagazig University Research Award for distinguished researchers (2016)
المشاريع البحثية
اسم المشروع وصف المشروع
Investigation of the potential physical and mental enhancement effects of Sesamol, Melatonin, and CoQ10 in Alzheimer’s Disease in rats Background: Alzheimer’s disease (AD) is a neurodegenerative disorder that characterized by a progressive decline of cognitive abilities Physical and mental activities (PH&M) have been related to better cognitive function in older adults Cognitive engagement and physical activities have been associated with decreased risk of AD Sesamol, Melatonin, CoQ10 are neuroprotective drugs that possess anti-inflammatory and antioxidant properties Aim: To evaluate the potential enhancement of Sesamol, Melatonin, CoQ10 and their selected combinations on the mental and physical activities on AD affected rats Methods: AD will be induced by ALCl3 (70mg/kg IP) every day for five weeks Physical and Mental activities PH&M exposed (swimming and Open field maze test) Sesamol, Melatonin, CoQ10 and their selected combinations will be administrated in parallel with ALCl3 (protective model) The effect of treatments will be assessed on animal behavior, brain neurotransmitters, biochemical changes in the brain monoamines, oxidative stress, pro-inflammatory cytokines, apoptosis Moreover, Histopathological changes in different brain regions, liver, kidney and heart and ultrastructural examinations will be performed
Design and synthesis of novel tubulin polymerization inhibitors as anticancer agents - Principal Investigator, KFU Deanship of Scientific Research grants 2009-2010: Grant number (10032/2009) Cancer is a major health care problem as one of the leading causes of death worldwide Recent revolutionary advances in the field of molecular biology and cancer cell biology have created new targets for antitumor compounds Amongst, tubulin retrieved a unique place as the most attractive target for anticancer drug research in the past decade In the present investigation, a systematic structure-activity relationship study will be formulated for pyrimido[4,5-c]quinolin-1(2H)-ones recently reported by us in order to “fine-tune their cytotoxicity and optimize binding to tubulin
Computer-assisted design and synthesis of novel aldose reductase inhibitors for prevention of diabetic complications - Principal Investigator, KACST (King Abdul-Aziz City for Science and Technology) grants 2010-2011: Grant number (APR-30-233) Diabetes mellitus is emerging as a major public health problem in Saudi Arabia The prevalence of diabetes in Saudi Arabia is about 24%, one of the highest in the world This pandemic will have a significant impact on the meager health resources of the kingdom, as diabetes is a chronic disease with devastating complications, including premature atherosclerotic cardiovascular diseases, sight-threatening retinopathy, renal failure and neuropathic diseases In addition, these complications lead to the exclusion of a significant proportion of the effective productive power of the society Compelling evidences accumulated over the past three decades clearly link aldose reductase enzyme, the key enzyme of the polyol pathway, with the initiation and progression of diabetic complications Consequently, inhibition of aldose reductase provides an attractive strategy to prevent or delay the onset of the complications of chronic diabetes Two major classes of aldose reductase inhibitors are currently available, acetic acid derivatives and the hydantoins and their bioisosteres Unfortunately, the majority of these drugs were withdrawn in different phases of clinical trials due to lack of efficacy, oral activity or due to adverse reactions The hydantoins and related bioisosteres are known to have better pharmacokinetics compared to acetic acid derivatives Among the compounds reported to have potent in vitro aldose reductase inhibitory activity are the indole-based acetic acid derivatives Yet as might be expected, these compounds may have low in vivo activity due to poor pharmacokinetics In this research project, we propose that replacement of the acetic acid moiety in this particular class of compounds by a hydantoin nucleus will significantly improve pharmacokinetics Meanwhile, high potency will be retained because the hydantoin ring is pharmacophoric to aldose reductase inhibition Selection of the target compounds was based on molecular modeling studies conducted on a number of spirohydantoins of certain fused indoles such as the carbazoles
معلومات التواصل
البريد الإلكتروني : kametwally@UT.EDU.SA
3912

الخصوصية وملفات تعريف الارتباط
هذا الموقع يستخدم ملفات تعريف الارتباط الخاصة للتأكد من سهولة الاستخدام وضمان تحسين تجربتك أثناء التصفح. من خلال الاستمرار في تصفح هذا الموقع، فإنك تقر بقبول استخدامنا لملفات تعريف الارتباط. الشروط والأحكام.